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Abstract: Melarsoprol administration for the treatment of late-stage human African 
trypanosomiasis (HAT) is associated with the development of an unpredictable and badly 
characterized encephalopathic syndrome (ES), probably of immune origin, that kills approximately 
50% of those affected. We investigated the characteristics and clinical risk factors for ES, as well as 
the association between the Human Leukocyte Antigen (HLA) complex and the risk for ES in a case-
control study. Late-stage Gambiense HAT patients treated with melarsoprol and developing ES (69 
cases) were compared to patients not suffering from the syndrome (207 controls). Patients were 
enrolled in six HAT treatment centres in Angola and in the Democratic Republic of Congo. 
Standardized clinical data was obtained from all participants before melarsoprol was initiated. Class 
I (HLA-A, HLA-B, HLA-Cw) and II (HLA-DR) alleles were determined by PCR-SSOP methods in 
62 ES cases and 189 controls. The principal ES pattern consisted in convulsions followed by a coma, 
whereas ES with exclusively mental changes was not observed. Oedema, bone pain, apathy, and a 
depressed humour were associated with a higher risk of ES, while abdominal pain, coma, 
respiratory distress, and a Babinski sign were associated with higher ES-associated mortality. 
Haplotype C*14/B*15 was associated with an elevated risk for ES (OR: 6.64; p-value: 0.008). 
Haplotypes A*23/C*14, A*23/B*15 and DR*07/B*58 also showed a weaker association with ES. This 
result supports the hypothesis that a genetically determined peculiar type of immune response 
confers susceptibility for ES. 
Keywords: human African trypanosomiasis; treatment; melarsoprol; adverse event; 
encephalopathy; human leukocyte antigen; association study 
 
1. Introduction 
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Human African trypanosomiasis (HAT, sleeping sickness) is a neglected tropical disease (NTD) 
caused by the protozoan parasites Trypanosoma brucei gambiense (Gambiense HAT, endemic in West 
and Central Africa) and Trypanosoma brucei rhodesiense (Rhodesiense HAT, endemic in Eastern and 
Southern Africa). The disease is transmitted through the bite of infected tsetse flies. HAT caused 
devastating epidemics at the beginning and the end of the 20th century [1]. As a consequence of 
intense and sustained control and surveillance activities which developed in endemic countries in 
the last 25 years, incidence levels were brought down to an all-time historical low (<1000) in 2018. 
However, HAT cases are still being reported in more than 20 countries in intertropical Africa. Most 
of the reported cases (98%) are of Gambiense HAT, which usually causes a chronic form of infection 
and in which humans are the main reservoir of the parasite. Rhodesiense HAT, a zoonotic disease 
that occasionally affects humans, usually causes a more acute form of disease and accounts for the 
remaining number of cases. HAT has been targeted by WHO for sustainable elimination by 2030. The 
essential component of the elimination strategy is the treatment of all diagnosed cases in order to 
deplete the parasite’s reservoir [2,3]. 
For over 50 years, successful treatment of sleeping sickness depended on correctly evaluating 
the degree of progression and severity of the disease. Following inoculation, infection remains 
temporally limited to the hemolymphatic system (hemolymphatic or early stage), but eventually 
progresses to central nervous system (CNS) invasion (meningo-encephalitic or late-stage). The 
transition between the early and late stage is insidious, and similar clinical features can exist in both 
stages [4]. The different penetration into the CNS, the pattern of adverse drug reactions, and the ease 
of use dictated the selection of the available drugs according to the disease stage until very recently. 
The early stage was treated with pentamidine or suramin because of the acceptable safety profile but 
insufficient drug levels in the cerebrospinal fluid (CSF). Late-stage T.b. gambiense HAT was typically 
treated with melarsoprol, and exceptionally with eflornithine. In 2009, the nifurtimox-eflornithine 
combination therapy (NECT) was added to the WHO essential drug list, replacing the more toxic 
drug, melarsoprol, as the first line of choice. NECT is, however, unreliable for the treatment of late-
stage Rhodesiense HAT, and in this condition, melarsoprol remains the first choice [5]. In 2018, the 
European Medicines Agency gave a positive scientific opinion on the new oral monotherapy 
fexinidazole for use against both stages of Gambiense HAT, and subsequently, a marketing 
authorization was issued in the Democratic Republic of Congo [6]. The WHO updated their treatment 
guidelines accordingly in August 2019; melarsoprol is now limited to treatment of late-stage T.b. 
rhodesiense and as the last treatment option for relapse cases in T.b. gambiense HAT [7]. Clinical 
research to assess the efficacy of fexinidazole against T.b. rhodesiense has recently been initiated 
(ClinicalTrials.gov Identifier: NCT03974178). 
Melarsoprol (ArsobalTM), introduced in 1949, was the first drug to efficiently treat both forms of 
late-stage HAT. Melarsoprol is the combination of melarsen oxide (a trivalent organic arsenical) with 
dimercaprol (British anti-lewisite, a heavy metal chelator developed as an antidote to arsenical-based 
nerve gases) [8]. Melarsoprol administration is associated with many adverse drug reactions, but the 
most severe and feared one is the encephalopathic syndrome (ES). ES is a badly defined, life-
threatening neurological complication. ES may occur at any time-point after the first melarsoprol 
administration and up to 30 days after the last one, with a median and peak occurrence around day 
nine of treatment [9]. The incidence of ES ranges from 2 to 10% of all melarsoprol treatments, and is 
associated with a case fatality rate (CFR) of about 50% [10]. In a systematic review on ES, the average 
frequency appeared to be higher in Rhodesiense HAT (8.0%) than in Gambiense HAT (4.7%), with a 
CFR of 57% and 44%, respectively [11]. Despite this significant impact and more than 50 years of 
extensive melarsoprol usage, sound scientific knowledge regarding ES is still scarce. 
Melarsoprol-associated ES is mostly described as consisting in the unpredictable and abrupt 
development of convulsions and intense agitation, followed by coma. However, descriptions of ES 
characterized only by convulsions or by the sudden onset of coma without previous convulsions also 
exist [12–15]. Based on restricted clinical–neuropathological correlation data, three independent 
forms of ES have been suggested, consisting in the separate existence of convulsions, coma, or mental 
(psychotic) changes. The severe and usually fatal coma type of ES is described as an acute 
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hemorrhagic leukoencephalitis that includes severe abnormalities in the brain stem, with fibrinoid 
necrosis of small vessels and ring and ball haemorrhages. It is not clear whether these forms 
correspond to the same etiology or if they are different phenomena. The prognosis of the three 
hypothetical forms also varies: coma, and to a lesser extent, convulsions are associated with high 
mortality, whereas the mental form is benign and self-limiting [16]. Furthermore, convulsions, 
episodes of decreased level of consciousness, and psychotic manifestations are common displays of 
the severe CNS damage that occurs in late-stage HAT [17]. 
The cause of ES was generally assumed to be an immune phenomenon occurring mainly in the 
CNS and involving a complex host–drug–parasite interaction [18–21]. The Human Leukocyte 
Antigen (HLA) complex is a gene complex encoding the major histocompatibility complex (MHC) 
proteins in humans [22]. HLA is accepted as the major determinant of the immune response in 
humans. HLA determines the differentiation between “self” and “non-self”, and is involved in auto-
immune diseases, as well as in determining susceptibility and resistance to several infectious diseases 
[23,24]. 
In order to improve the definition of the syndrome, to identify and quantify clinical risk factors 
for ES and for the ES case fatality rate, and also to determine whether an association between ES and 
Class I and II HLA antigens exists, we designed and conducted a case-control study with prospective 
data collection on the encephalopathic syndrome during treatment of late-stage Gambiense HAT 
with melarsoprol. 
2. Materials and Methods  
2.1. Study Design and Conduct 
This was a case-control, non-blinded, non-randomized, non-interventive, multi-centre study, 
with prospective (i.e., before the patients were treated with melarsoprol) clinical data collection. Late-
stage Gambiense HAT patients treated with melarsoprol and who developed or did not develop an 
encephalopathic syndrome were compared. The design of the study was nonparametric and aimed 
at testing whether or not the alleles of the HLA markers were distributed at random in patients 
suffering from ES [25]. The study was conducted from June 2002 in Angola and August 2002 in the 
DRC to November 2003. 
Clearances were obtained from the ethical independent ethics committees of both Cantons of 
Basel (Switzerland) (Protocol approved under number 189/01), and of the Ministries of Health in 
Luanda (Angola) and Kinshasa (DRC). Informed consent was obtained from all participants or their 
legal tutors. 
2.2. Study Sites 
Participants were enrolled in six specialized HAT treatment centres supervised by the Instituto 
de Combate e Controlo das Tripanossomíases (ICCT) in Angola or by the Programme National de 
Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA) in the Democratic Republic of Congo. 
In Angola, these centres were the Centro de Referência e Investigação de Viana (Luanda), 
N’Dalatando (Kwanza Norte Province), and Uíge (Uíge Province). In the DRC, participating centres 
were Mbuji Mayi (Kasai Oriental Province), Maluku (Kinshasa), and the Centre Neuro-Psycho-
Pathologique (CNPP), Kinshasa. 
2.3. Study Population 
Inclusion criteria for cases and controls were as follows: (1) the patient had T. b. gambiense 
infection (confirmed either serologically or parasitologically in blood or lymph) and trypanosomes 
in CSF and/or CSF WBC count > 5 cells/mm3 and/or clearly defined neurological signs; (2) the patient 
was treated with melarsoprol; (3) the patient was conscious at admission (Coma Score ≥ 9 in the 
modified Glasgow Coma Scale) and was not convulsing before the start of melarsoprol treatment; 
and (4) mental changes of the psychotic type were not reported in the anamnesis or observed before 
the start of melarsoprol treatment. A patient was considered a case of encephalopathic syndrome 
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when the following criteria were fulfilled: (1) onset of coma; (2) onset of convulsions; and (3) onset of 
severe mental symptoms, such as psychotic reactions and/or abnormal behaviour (aggressivity, 
severe confusion or disorientation) requiring a therapeutic intervention. 
Exclusion criteria for both cases and controls were as follows: (1) the patient received 
melarsoprol in association with any other anti-trypanosomal drug; (2) patient follow-up could not be 
assured for 30 days after discharge. 
For each ES case, three controls were enrolled. The controls were selected as the next three HAT 
patients following an ES case who underwent final discharge examination after having successfully 
completed treatment with melarsoprol, and did not develop ES during the follow-up period (to cover 
for the rare possibility of a late-onset ES). 
2.4. Study Methodology 
Detailed clinical data was obtained from every admitted late-stage HAT patient (and/or from 
relatives) before melarsoprol was initiated and recorded in a Case Report Form (CRF). When a patient 
developed an ES, the characteristics of the clinical presentation, of the management and of the final 
outcome of the syndrome were additionally inserted into the CRF. 
Management of HAT patients (i.e., admission, diagnosis, treatment, discharge, and follow-up) 
and of ES cases in the participating centres followed the guidelines established by the respective 
national program. A microscopic test for Plasmodium was performed if the development of an ES was 
suspected in a patient. The test result was made available to the clinical staff for adequate 
management of the patient. No additional changes in routine procedures were introduced. 
Blood sample collection for HLA typing was performed once the diagnosis of ES was established 
(cases) and at discharge for controls. Blood was collected onto filter paper cards (Generation® Sample 
Collection Cards, Gentra Systems, MN, USA). Dried blood-spotted cards were inserted into sealable 
plastic bags and stored at room temperature. 
2.5. Data Management 
Data on CRFs was checked for inclusion and exclusion criteria and for completeness and 
consistency. Missing data and clarifications were obtained from the local investigators. Data from the 
CRFs was double-entered into two EpiData (http://epidata.dk/) databases—one for the demographic 
and clinical information of cases and controls, and the other for the description of ES cases. For 
analysis, the databases were merged and exported to the SPSS software package (SPSS for Windows, 
Rel. 15.5.0. 2002. SPSS Inc.,Chicago, IL, USA). 
2.6. HLA Typization 
HLA typing was performed at the Molecular Genetics Laboratory of the Centro de 
Histocompatibilidade do Norte (North Histocompatibility Centre, CHN), Porto, Portugal, the 
reference facility for HLA typing for transplantation patients in Northern Portugal. Samples were 
typed for Class I HLA-A, HLA-B, and HLA-Cw molecules, and for Class II molecules of the HLA-
DRB1 category using two different commercially available PCR-based reverse line blot assays that 
detect specific target DNA sequences by means of multiple immobilized sequence-specific 
oligonucleotide (SSO) probes [26–29]. The Dynal RELI™ SSO HLA Test (developed by Roche 
Molecular Systems, Inc. and manufactured by Dynal Biotech Ltd., Wirral, UK) for Class I molecules 
and the INNO-LiPA HLA-DRB1 Amplification and Hybridization Test (Innogenetics, Ghent, 
Belgium) for Class II molecules were used. 
Hybridization was performed using an AutoLIPA (Innogenetics, Ghent, Belgium) automated 
assay processor, programmed to fit the Dynal RELI™ SSO HLA or the INNO-LiPA HLA-DRB1 
hybridisation tests. To obtain the final HLA type, patterns were interpreted using the Dynal RELI 
SSO Pattern Matching Program, version 5.11 for Class I molecules (http://imgt.cines.fr) (Lefranc, 2003) 
or the LiPA interpretation software LiRAS™ for Class II molecules (using the latest available version 
from Abbott). 
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2.7. Statistical Analysis 
Clinical data of ES cases and controls were compared using Pearson’s Χ2 or Fisher’s test. Risk 
factors for ES and death from ES were assessed by calculating the corresponding Odds Ratio (OR) 
and the 95% confidence interval (CI) for binomial variables. The numeric variables’ age and white 
blood cell count (WBC) in CSF were split into quartiles, and the Mann–Whitney test was used to 
compare medians; standard residual values while applying the Χ2 test were checked for values above > 
[1.96]. For evaluation of the body mass index (BMI) and patient general status on admission, 
proportions were compared by cross tabulation. Three categories were defined for BMI, 
corresponding to severe malnutrition (BMI ≤ 18), moderate malnutrition (BMI > 18 and ≤20), and 
normal nutritional status (BMI > 20). General status was categorized as “Bad”, “Fair”, or “Good”. 
For the analysis of the relationship between HLA type and the frequency of ES, allele frequencies 
were compared among cases and controls by determining the p value of the Χ2 test applied to a 2 × 2 
contingency table. OR and CI were obtained for alleles showing a significant p value. Haplotype 
frequencies were calculated assuming that the two allele loci were in linkage disequilibrium (LD). 
LD parameter ∆ was obtained by constructing a 2 × 2 contingency table and applying the formula 
originally described by Bodmer and Bodmer in 1970 [30]. LD ∆ was then added to the product of 
allele frequencies. Significant differences in haplotype frequency in cases and controls were 
subsequently obtained using the Χ2 test with Fisher’s exact test, with the OR and CI. 
3. Results 
Case Report Forms of 76 potential cases of encephalopathic syndrome (ES) were received. After 
checking for inclusion and exclusion criteria, 69 ES cases and 207 control patients were retained and 
included for analysis. The center of enrolment and outcome of ES patients are described in Table 1.  
Table 1. Origin and outcome of enrolled ES patients. 
HAT Treatment Centre Number of ES Patients Deaths 
Mbuji Mayi (DRC) 24 (35%) 10 (41.6%) 
Viana (Angola) 21 (30%) 10 (47.6%) 
Maluku (DRC) 8 (12%) 4 (50%) 
Uíge (Angola) 7 (10%) 4 (57.1%) 
N’Dalatando (Angola) 6 (9%) 3 (50%) 
CNPP (DRC) 3 (4%) 1 (33.3%) 
Thirty (43.3%) patients were female and 39 (56.5%) were male. The age of ES patients ranged 
from 4 to 67 years, with median and mean values of 26 and 30.6 years, respectively (std. deviation: 
14.6 years). Three patients were less than 10 years old, and two patients were above 60 years. Ethnic 
heterogeneity in the study population was considerable. In Angola, patients belonged to the 
Kimbondo, Kikongo, Ovimbundo, and Bakongo ethnic groups. The determination of ethnic groups 
was not available in the DRC, since only the village of birth of the patient was recorded, due to 
difficulties found in attributing the correct ethnic group to individuals. All but five patients had 
parasitologically confirmed HAT. These five patients had been previously treated with pentamidine; 
late-stage HAT diagnosis was established according to a positive card agglutination test for 
trypanosomiasis (CATT) and more than 5 WBC/mm3 in CSF. All patients were treated according to 
the abridged IMPAMEL schedule (2.2 mg/kg/day of melarsoprol for 10 consecutive days). 
3.1. Characteristics of the Encephalopathic Syndrome 
3.1.1. Clinical Features 
ES was mainly characterized by convulsions followed by coma. Variations consisting of isolated 
convulsions or coma without convulsions occurred with lower frequencies (Table 2). Convulsions 
were observed in 85.5% of all cases, and 71% of the convulsive episodes were multiple. Convulsions 
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led to coma in 55% of all ES cases, whereas coma not preceded by convulsions was observed in 14.5% 
of all ES cases. For coma characterization, we used a modified Glasgow Score, where unarousable 
coma is associated with a score of 7 or less. During the ES episode, the mean minimal score was 4.8, 
with a median score of 5 (Std. Deviation: 2.6) and the mean maximal score was 6.3, with a median 
score of 6 (Std. Deviation: 2.5). Additional signs, such as fever and maculopapular cutaneous lesions, 
were more frequent in the subgroup developing convulsions followed by coma (52% of cases 
developing fever and maculopapular lesions) than in the coma (20%) and convulsive (5%) sub-groups, 
respectively. The mental type of ES was not observed in the study. 
Table 2. Type of manifestation of ES observed and discriminated according to the outcome. The 
existence of fever and/or maculopapular cutaneous eruption (urticaria) is also indicated. 
Type of 
Manifestation of ES 
Cases 
N/(%) 
Outcome 
Survival 
n/% 
Additional 
Signs 
n 
Outcome 
Death 
N/% 
Additional 
Signs 
n 
Convulsion and coma 38/(55) 13/(18.8) 
Fever in 3 
Urticaria in 3 
Fever and 
urticaria in 1 
25/(36.2) 
Fever in 15 
Urticaria in 7 
Fever and 
urticarial 
in 5 
Convulsion without 
coma 
21/(30.5) 19/(27.5) 
Fever in 6 
Urticaria in 4 
Fever and 
urticaria in 2 
2/(2.9) Fever in 1 
Coma without 
Convulsions 10/(14.5) 
5/(7.2) 
Fever in 2 
Fever and 
urticaria in 1 
5/(7.2) Fever in 2 
Urticaria in 1 
Totals 69/(100) 37/(53.6) 
Fever in 11 
Urticaria in 7 
Fever and 
urticaria in 4 
32/(46.4) 
Fever in 18 
Urticaria in 8 
Fever and 
urticaria in 6 
Additional symptoms and signs characterizing ES cases and corresponding degrees are shown 
in Table 3. Degree 1 was defined as transient, mild, or localized. Degree 2 was defined as durable and 
needing intervention, intolerable, severe, or diffuse. For fever, Degree 1 was defined as 37.5–38.9 °C, 
and Degree 2 as more than 39 °C. For tachycardia, Degree 1 was defined as less than 100 bpm, and 
Degree 2 as more than 100 bpm. For hypotension, Degree 1 was defined as systolic blood pressure 
less than 80 mmHg, and Degree 2 as shock. Fundoscopic examination was not performed in ES 
patients. 
Table 3. Symptoms and signs characterizing ES, according to the global frequency and discriminated 
for the degree of severity. 
Characterization of ES 
Symptoms and Signs 
Frequency 
(Global) 
% (n)  
Frequency  
(Degree 1) 
% 
Frequency  
(Degree 2) 
% 
Malaise 79.7 (55) 20.3 59.4 
Confusional state 78.3 (51) 26.1 52.2 
Fever 69.6 (48) 52.2 17.4 
Agitation 65.2 (45) 34.8 30.4 
Tachycardia 60.9 (42) 39.1 21.7 
Respiratory distress 59.4 (41) 36.2 23.2 
Headache 56.5 (39) 37.7 18.8 
Apathy 56.5 (39) 24.6 31.9 
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Maculopapular eruption 50.7 (35) 10.1 40.6 
Chills 36.2 (25) 24.6 11.6 
Red eye syndrome 33.3 (23) 33.3 0 
Vertigo 29.0 (20) 20.3 8.7 
Oedema (facial) 23.2 (16) 23.2 0 
Vomiting 23.2 (16) 14.5 8.7 
Babinski sign 20.3 (14) 20.3 0 
Panic attack 18.8 (13) 14.5 4.3 
Nausea 18.8 (13) 13.0 5.8 
Hypotension 15.9 (11) 13.0 2.9 
Hallucinations 10.1 (07) 8.7 1.4 
Delirium 10.1 (07) 0 10.1 
Nucal rigidity 10.1 (07) 10.1 0 
Aggressive behaviour 07.2 (05) 4.3 2.9 
More than half of the ES patients developed a deep malaise, entered a confusional status, and 
had fever. Apathy and agitation periods were frequent and could alternate. Two thirds of the patients 
were tachycardic, but hypotension was present in only 16% of them. Respiratory distress, consisting 
mainly in irregular respiratory patterns, frequently complicated the advanced phase of ES, preceding 
death. Nausea and vomiting were present in less than one quarter of the patients. A maculopapular 
eruption, conjunctival hyperaemia (red eye syndrome), or facial oedema were observed in half, one 
third, and one fifth of the patients, respectively. Additional signs observed were vertigo in up to one 
third of the patients and psychotic manifestations (hallucinations, delirium, panic attack, or 
aggressive behaviour), present in around one tenth of the patients. Damage to the cortical spinal tract, 
demonstrated by the Babinski sign, was present in one third of the patients. Meningeal irritation, 
demonstrated by neck rigidity, was observed in only 10% of the patients. Clinical signs of bleeding 
disorder were not observed. 
3.1.2. Laboratory Evaluation of ES 
Laboratory evaluation (haemoglobin, leukocyte count in blood and in CSF) within the duration 
of the ES episode was performed in 15 patients. Neither the leukocyte differential blood count nor 
the platelet counts were available. ES patients did not show severe anaemia or significant changes in 
the leukocyte blood count. To check for bacterial meningitis, a Gram-stained smear was performed 
in 14 CSF samples, always with a negative result. In 11 patients, CSF glucose content was also 
obtained, but was not simultaneously measured in blood. Half of the patients had glucose levels in 
CSF close to or below the accepted inferior limit of 50 mg/dL. No increase above the WBC count in 
CSF on admission was observed during ES. Plasmodium smear was negative in all ES cases evaluated 
for CSF parameters. Additional laboratory parameters for hepatic, renal, respiratory, and metabolic 
evaluation were not available at the Centres. 
3.1.3. Time Point and Outcome for ES 
The mean and median numbers of melarsoprol applications associated with the development of 
ES were 8.5 and 9 doses, respectively (Std. Deviation: 1.9; range: 2 to 10 doses). Melarsoprol was 
administered on consecutive days in all cases, except in one hypertensive patient due to hypertension 
peaks, in whom with treatment was interrupted for 2 days; 47.8% of patients developed ES with the 
10th dose of melarsoprol. The number of melarsoprol administrations preceding the development of 
ES was not significantly different whether the initial manifestation of ES consisted of coma or 
convulsions (p value of the Mann–Whitney test: 0.26; all observed counts not statistically different 
from to those expected: all std. residuals below 1.96). 
The mean time interval between the last application of melarsoprol and start of ES was 35.4 h. 
This interval is the time between melarsoprol administration and the development of symptoms and 
signs of an impending encephalopathy, during which subsequent doses of the drug are withheld. 
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Half of the patients developed ES within 23.5 h after the last application, and 75% did so 47.7 h within 
the last drug application. Figure 1 shows the median time interval distribution for the development 
of ES after the last melarsoprol application, discriminated according to the outcome of ES. The 
interval for the occurrence of ES after the last dose of melarsoprol before ES was not significantly 
different between survivors and fatalities (Mann–Whitney test, p value: 0.08). 
 
Figure 1. Time interval in hours for the occurrence of ES after the last melarsoprol application 
according to the final outcome. The inbox line in bold indicates the median. Outliers and extremes are 
not shown. 
Encephalopathic syndromes led to a fatal outcome in 32 patients (46.4%). On average, death 
occurred 2.5 days after diagnosis of the syndrome (median: 1 day; std. deviation: 2.9 days; range 0–
13 days). 80.6% of the patients died within three days after developing ES. 
On average, ES manifestations ceased 2.2 days after initiation of the episode in the 37 surviving 
patients. The majority of surviving patients (73%) did not show any sequelae on discharge. When 
present, sequelae consisted in tremors (three cases), mental changes (confusion, euphoria, 
aggressivity) (three cases), paraplegia (two cases, one with urinary retention), speech disturbances 
(polylalia, dysarthria, aphasia) (three cases), and walking disability (one case). 
3.1.4. Patient Management 
All centres used corticosteroids (prednisone, hydrocortisone, occasionally combined with 
promethazine), antimalarials (chloroquine, sulfadoxine-pyrimethamine, or quinine), and 
anthelminthics (mebendazole, levamisole) and multivitamins for “patient preparation” before 
melarsoprol administration, aiming at reducing its toxicity. 
All ES patients were managed with corticosteroids, except two patients (that survived). Half of 
the patients under corticosteroid therapy for ES died. Convulsions were managed with standard 
doses of diazepam and/or phenobarbital, which were frequently used simultaneously with 
promethazine. The difference in outcome in patients using the three diverse types of antipyretic 
(paracetamol, acetyl salicylic acid, or dipyrone) was not significant. Antibiotics (mainly ampicillin, in 
one patient in combination with gentamicin) were used when a severe bacterial infection, usually 
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respiratory, was suspected during ES. The use of quinine, mannitol, furosemide, and adrenaline was 
associated with high mortality. No evident anomalies in the prescribed dosage of the drugs were 
detected. 
Intravenous fluids (5% glucose in water or Ringer lactate) were used in 61 patients. A urethral 
catheter was inserted in 40 patients, and a nasogastric tube was used in 13. However, monitoring of 
fluid and caloric input/output was never recorded. Medical oxygen was not available in the centres. 
3.2. Risk Factors for the Encephalopathic Syndrome 
3.2.1. Clinical Factors 
All variables in the questionnaire were analysed to determine if they constituted risk factors for 
the development of ES or for death from ES. Table 4 shows the variables obtained on admission that 
yielded a significant p value (<0.05) highlighted in bold. Selected variables with a higher p value when 
the OR indicated a tendency (≥2), even when the lower limit of the 95% CI was below 1, are also 
indicated. All other variables were below this threshold, and yielded insignificant p or OR values. 
Patients reporting oedema in history or with apathy and/or depressed humour in the physical 
exam had a significant risk of developing ES. Patients who reported with abdominal pain, 
conjunctivitis, or pruritus in the anamnesis had a higher risk of dying from ES. 
Table 4. Anamnesis, physical examination, and laboratory variables obtained during admission and 
corresponding statistical tests for association with the development of ES or death from ES. 
Variable Encephalopathy Death 
 OR 95% CI p OR 95% CI p 
Anamnesis       
Oedema 4.0 1.0–15.4 0.03 1.8 0.2–11.5 0.09 
Bone pain 2.3 1.2–4.3 0.10    
Paralysis 3.0 0.4–22.0 0.20    
Hypoestesia 2.0 0.3–12.2 0.40    
Abdominal pain    4.5 1.5–14.0 0.006 
Conjunctivitis    3.0 1.0–8.7 0.03 
Pruritus    3.0 1.0–8.7 0.04 
Adenomegaly    2.2 0.7–6.1 0.1 
Weight loss    2 0.6–6.6 0.2 
Weakness/asthenia    2 0.5–7.4 0.3 
Diarrhoea    4.9 0.9–25.6 0.4 
Physical examination       
Apathy 1.9 1.0–3.8 0.04    
Depression 1.9 0.9–4.2 0.07    
Facial paralysis 3.5 0.6–17.8 0.1    
Incomprehensible 
Speech 2.2 0.5–7.7 0.2    
Babinski 2.2 0.6–7.7 0.3 3.6 0.4–36.7  0.2 
Pale mucosa    2.4 0.2–27.7 0.4 
Neck rigidity    2.4 0.2–27.7 0.4 
Splenomegaly    2.8 0.2–33.6 0.4 
Agitation    2.4 0.2–27.7 0.5 
During the ES episode, coma (OR: 2.4, p value < 0.001), respiratory distress (OR: 5, p value: 0.002) 
and a Babinski sign (OR: 3.8, p value: 0.04) were significantly associated with death. Coma usually 
developed after convulsions, and respiratory distress often appeared as a terminal event. Respiratory 
distress was apparently not due to iatrogenic pulmonary oedema (no reference to physical signs of it 
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was found). Tachycardia, hypotension, and, to a lesser extent, agitation were also marginally 
associated with death. 
3.2.2. Laboratory Data 
Laboratory evaluation on admission showed that none of the measured biological markers 
(Haemoglobin, WBC count in blood or in CSF) was clearly associated with the occurrence of ES. CSF 
WBC count on admission was analysed by dividing the results of the count in quartiles. The limit for 
the first quartile was found to be 100 WBC/mm3 in the CSF. Additionally, the more conventional 
division of WBC count in CSF (less than 20 cells, 21 to 100 cells, and more than 100 cells in CSF) was 
also used in analysis (data not shown). Trypanosomes were found more frequently in the lymph (p 
value: 0.2, OR: 1.8) and in the CSF (p value: 0.2, OR: 2.2) of patients who developed ES, but possibly 
due to the small numbers, the difference was not statistically significant. 
3.2.3. Concomitant Diseases 
Of the 58 patients tested for malaria during ES, 13 (22.4%) were positive (thick smear) and 8 (61%) 
died, while 45 (77.6%) were negative and 23 (51%) died. 
Diagnosis of other concomitant diseases on admission included oral candidosis, lymphatic 
filariasis, pulmonary tuberculosis, and orchitis in one patient each. The patient with oral candidosis 
did not develop ES, and the three others died from ES. During ES, a clinical diagnosis of respiratory 
infection was clearly established in two patients, and thereof, one died. 
3.2.4. HLA Type 
Alleles for every tested HLA category could be clearly determined for 62 ES cases and 189 
controls. Samples showing any ambiguity in allele determination were excluded from the analysis. 
The statistical association between the HLA type and the development of ES is shown in Table 5. 
Deducted haplotype C*14/B*15 was associated with a risk more than 6.5 times higher of 
developing ES. The association is significant (p value: 0.008), but the upper limit of the CI is 
considerably large. Haplotype A*23/C*14 was also found to be potentially associated with ES (p value 
less than 0.05), with a risk nearly 10 times greater of developing ES with this haplotype, but the 
inferior limit of the CI is below one, suggesting that a greater number of patients is needed for 
confirmation. A*23/B*15 and DR*07/B*58 showed a tendency for association with ES, but the level of 
significance for these allele combinations is above a p value of 0.05. 
Table 5. Frequency of deducted haplotypes in cases and controls, with OR and CI. (*) indicates 
Fisher’s test was used. LD: linkage disequilibrium. 
 Cases Controls p OR CI LD Cases 
C*14/B*15 6/62 3/189 0.008 (*) 6.64 1.35–41.96 0.038 
A*23/C*14 3/62 1/189 0.04 (*) 9.56 0.74–50.4 0.01 
A*23/B*15 13/62 22/189 0.06 2.0 0.88–4.56 0.04 
DR*07/B*58 5/62 5/189 0.07 (*) 3.23 0.71–14.49 0.017 
4. Discussion 
4.1. Characteristics of ES 
Until today, this is the largest single study on ES patients that has ever been conducted. So far, 
the results were only published as a chapter of a PhD thesis [11]. When the study was carried out, 
melarsoprol was still the only routine option to treat late-stage HAT. Still, the findings have relevance 
today, since T.b. rhodesiense is still treated with this organoarsenic drug, even if we cannot affirm with 
complete confidence that the risk factors we found in our study will apply to ES associated with this 
form of sleeping sickness. Nevertheless, our findings are important because they contribute to the 
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understanding of immunological processes in the development of severe adverse drug reactions in 
the brain. 
The results are in line with the majority of publications describing ES. However, they do not 
support the hypothesis formulated in two publications that three separate forms of the phenomenon 
exist [9,16], which may rather be the result of observational bias. Our findings, derived from a multi-
center prospective study specifically designed to investigate ES and therefore being potentially less 
bias-prone, suggest that full-blown ES consists in multiple convulsions, where half of the cases are 
followed by a deep coma. Variations consisting in isolated convulsions or coma without convulsions 
occurred with lower frequencies around this main pattern. Additional signs, such as fever and 
maculopapular cutaneous lesions, were more frequent in the subgroup developing convulsions 
followed by coma than in the coma and convulsive sub-groups. Patients showed profound malaise, 
mental confusion, and apathy alternating with agitation and tachycardia. Additional signs consisting 
in conjunctival hyperaemia and facial oedema were present in 1/3 and 1/5 of the patients, respectively. 
The exclusively mental type of ES was not observed in the study. Four cases were initially 
enrolled as belonging to the exclusively mental type of ES. They were, however, excluded from 
analysis after the presence of severe mental changes in anamnesis in the course of HAT was detected 
prior to melarsoprol application. This suggests that previous descriptions of this hypothetical type of 
ES may also suffer from an observational bias, with mental changes already present but not detected 
in the patient history or under-evaluated in clinical examination. Alternatively, we may speculate 
that if an exclusively mental type of ES exists, the frequency of the phenomenon is probably very low. 
Our patients were all treated with the consecutive 10 day melarsoprol schedule, which has been 
recommended by the International Scientific Council for Trypanosomiasis Research and Control for 
late-stage Gambiense HAT in 2003 and by the WHO in 2013 [5], in substitution of older complicated 
schemes [31]. In accordance with previous data [9], we could confirm that ES occurs preferably after 
the eighth dose of melarsoprol, and in half of the cases, with the 10th dose. The time-point for 
occurrence and the prognosis of ES have been the basis for discussions about the etiology and severity 
of the phenomenon. It has been shown that ES occurs at the same average point in time, independent 
of whether the abridged 10 consecutive days’ constant dosage melarsoprol scheme or an older 
scheme of progressively increasing intermittent dosage (three series of 4 days with a 7 day interval) 
is used [31]. A subsequent study showed that both the coma and the convulsive types of ES also tend 
to occur at the same time-point [9]). In our study, the number of days elapsing before ES developed 
was similar for both initial manifestations of ES (coma or convulsions) and for the outcome (survival 
or death). A higher lethality of the hypothetical coma type of ES is described in the literature [9,16]. 
Our findings indicate that the highest mortality (36.2%) was instead associated with convulsions 
followed by coma (observed in 55% of the ES cases). Together with our findings on HLA involvement, 
these results give evidence that ES is an immunological phenomenon and that the different clinical 
presentations correspond to different severities of the same pathogenetic mechanisms. Further 
evidence might come from clinical–neuropathological correlation studies, as they would permit 
confirming the similarities between the neuropathological characteristics of ES and acute 
hemorrhagic leukoencephalitis (AHLE, Hurst disease), which is considered the most severe form of 
acute disseminated encephalomyelitis (ADEM). Patients with Hurst disease usually develop a severe 
CNS condition but, like in ES, different clinical expressions exist [32]). The anatomopathological 
changes found in AHLE [33] are very similar to the ones described in the coma type of ES by Haller 
in 1986. 
In the literature, the development or intensification of unspecific signs, such as fever, headache, 
nausea, vomiting, dizziness, tremors, and conjunctival hyperaemia are considered leading signs of 
ES [34]. The search for distinct heralding signs of ES was an objective of our study protocol, but except 
for fever, they were generally not reported. However, the fact that clinicians stopped melarsoprol 
administration in an average of 35.4 h before the inclusion criteria for ES were reached indicates that 
they suspected the development of the complication. 
In 80% of the patients reaching a fatal outcome, death occurred within three days. Surviving 
patients mostly recovered completely from ES in less than three days. These facts stress the need for 
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careful and adequate patient surveillance while under treatment with melarsoprol so that a prompt 
diagnosis of ES can be made, and adequate therapeutic measures swiftly initiated. A lethal outcome 
was the result of ES in nearly half (46.4%) of the cases, with non-significant differences among the 
participating centres, which is within the range of mortality for ES in Gambiense HAT found in the 
literature. 
None of the limited laboratory variables (haemoglobin and leukocyte count in blood and in CSF) 
evaluated during ES (rarely reported in the literature) in 15 patients proved useful in the confirmation 
of an ES diagnosis. We may conclude that there are no useful laboratory markers of ES available for 
use in the resource-limited rural African health facilities. However, glucose levels in CSF were close 
to or below the accepted inferior limit of 50 mg/dL in half of the patients, suggesting that low glucose 
levels in CSF, a potential triggering factor for convulsions, may be frequent in ES. To the best of our 
knowledge, this original finding could be important for patient management. The CSF Gram stain 
obtained in 14 ES patients was always negative, showing (with some degree of confidence) that ES 
patients in the study did not suffer from a confounding and potentially treatable bacterial 
meningoencephalitis. 
4.2. Risk Factors for ES 
Haplotype C*14/B*15 was significantly associated with ES. Three additional haplotypes 
(A*23/B*15, A*23/C*14, and DR*07/B*58) showed lesser degrees of association with ES, but sample 
size was insufficient for adequate statistical power. Alternatively, we may consider that the genetic 
component of ES could be polygenic or associated with a single major locus with other loci of small 
effect. The ethnical diversity observed in the clinical study was considerable, and the low numbers 
in the different ethnic groups was not sufficient to allow for sufficiently statistically powered ethnic 
stratification. As usual in genetic association studies, confirmation of these results would be needed 
in other populations. However, our data does suggest that there is a genetic predisposition for ES. 
This finding is in line with the described association between acute hemorrhagic leukoencephalitis 
(AHLE, Hurst disease), and particular, HLA haplotypes [32]. Since the physical map of the HLA 
complex genes is now available, it would be possible to explore the molecular basis of ES. Linkage of 
the Class II allele found in the study with Class III genes or non-HLA genes involved in the immune 
response, especially those related to the synthesis of the cytokines and mediators described in late-
stage HAT could be explored to gain further insight into the etiology and pathogenesis of ES. 
The following risk factors were consistently identified for ES and for death from ES, respectively: 
oedema, apathy, and a depressed humour; as well as abdominal pain, pruritus, and conjunctivitis. 
Additional variables, such as diarrhoea in patient history and facial paralysis and a positive Babinski 
sign on examination yielded elevated OR values, but their p values were below statistical significance. 
However, the identified symptoms and signs may be transitory and elusive, and may need a careful 
and detailed evaluation of the patient, which clearly limits their practical value, especially in the 
African setting. The absence of a clear association between elevated WBC in CSF and presence of 
trypanosomes in body compartments conflicts with findings from previous studies [9,10,18]. 
Concomitant infections, particularly malaria, have long been suspected of increasing the risk of 
ES [9,35]. The issue of concomitant infections and melarsoprol adverse events, including ES, was 
addressed in a large cohort of patients treated with a concise 10 day schedule [36]. Malaria parasites 
were found in 22.7% (40/176) of the patients suffering from ES, despite the fact that, as in our study, 
all patients received a full course of chloroquine or sulfadoxine and pyrimethamine or quinine during 
the preparation period prior to melarsoprol. In our study, 22.4% (13/58) of the patients showed a 
positive smear during ES. The role of Plasmodium infection in ES is difficult to establish, and its 
analysis is inherently associated with the quality of the malaria diagnosis, which was frequently low 
in the participating centres. 
Malnutrition is very frequent in patients suffering from HAT. In one report, more than 20% of 
adults and 56% of the children with Gambiense HAT were affected [37]. A deficient nutritional status 
and a bad general status are empirically considered as having a significant impact on the risk for ES. 
However, in our clinical study, neither the general status nor the BMI was correlated with ES or death 
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from ES, which is in accordance with the findings from a large and adequately powered melarsoprol 
trial (IMPAMEL II) [35]. 
4.3. Patient Management 
Because this was a non-interventive study, and given the multiplicity of the drugs used and the 
low number of patients enrolled in some centres, we could not evaluate the usefulness of the 
individual drugs (prednisone, antimalarials, anthelminthics, and multivitamins) used for prevention 
of ES. Corticosteroids are presently accepted as beneficial in the prevention of ES and widely used 
for this purpose, but the validity of this intervention is not based on solid evidence [10,11,34]. 
Management of ES patients in our study with dexamethasone was associated with lower 
mortality (38.5%) when compared to hydrocortisone (50%), which was the most frequently used 
corticosteroid. Hydrocortisone has a high sodium retention action when used at the dose needed to 
reach significant anti-cerebral oedema action, and may contribute to water retention and pulmonary 
oedema. Dexamethasone, used as in cerebral oedema, offers a more adequate pharmacological profile, 
and this could explain the tendency for a lower mortality observed with this drug in our study. 
Limited evidence shows that methylprednisolone, in high (5 to 10 mg/kg/day) or very high (1000 
mg/day for an adult) doses, may be useful in critical patients with viral encephalitis, acute 
disseminated encephalomyelitis (ADEM), and AHLE [38,39]. Such high-dose methylprednisolone 
schemes could be suitable in ES, given the similarities between these conditions and ES. 
Quinine, furosemide, mannitol, and adrenaline can promote or increase cardiovascular 
arrhythmias, hypoglycaemia, and fluid and electrolyte imbalance, which, in addition to the frequent 
severe clinical deterioration of ES patients, may explain the high mortality associated with these 
drugs in our study. Their use in a critically ill ES patient is hazardous (especially without good 
monitoring equipment and as a combination) and should probably be limited to patients with 
accurately diagnosed malaria, strong evidence of fluid overload, raised intracranial pressure, shock, 
or severe bacterial infection. 
Human African trypanosomiasis is nowadays considered a rare disease targeted for elimination 
[40]. Melarsoprol use in HAT is presently limited to rescue therapy of cases refractory to other drug 
treatments in Gambiense HAT and to Rhodesiense HAT late-stage patients, meaning that 
melarsoprol-related ES will become a rare event. In our opinion, this also means that patients in need 
of melarsoprol treatment should preferably be referred to specialized centres where knowledge on 
the correct management of complications associated with the use of this powerful but dangerous 
drug persists. 
5. Conclusions 
In conclusion, our study obtained a more precise definition of ES, which is useful in the correct 
diagnosis of the condition. The observed clinical risks factors for ES were elusive. A significant 
statistical association between Class I haplotype C*14/B*15 and ES was found. Patients expressing 
this haplotype have an almost 6.5 times higher risk of developing ES. Additionally, three other 
haplotypes were found to be possibly related to ES. This finding corroborates our hypothesis of an 
immunological involvement in the pathogenesis of ES. This result indicates that a genetically 
determined individual susceptibility exists that produces a peculiar type of immune response in the 
central nervous system that, in combination with the presence of trypanosomes and melarsoprol, 
results in a catastrophic condition in many aspects similar to acute hemorrhagic leukoencephalitis 
(AHLE, Hurst disease). 
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